UBIO's Holdings Could Mean 18% Gain Potential
Thu, Aug 17, 8:44 AM ET, by ETF Channel
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares UltraPro Nasdaq Biotechnology ETF (UBIO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $37.25 per unit.
With UBIO trading at a recent price near $31.45 per unit, that means that analysts see 18.44% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of UBIO's underlying holdings with notable upside to their analyst target prices are Cytokinetics Inc (CYTK), Aratana Therapeutics, Inc (PETX), and ChemoCentryx, Inc. (CCXI). Although CYTK has traded at a recent price of $12.45/share, the average analyst target is 82.06% higher at $22.67/share. Similarly, PETX has 81.16% upside from the recent share price of $5.52 if the average analyst target price of $10.00/share is reached, and analysts on average are expecting CCXI to reach a target price of $13.00/share, which is 79.31% above the recent price of $7.25. Below is a twelve month price history chart comparing the stock performance of CYTK, PETX, and CCXI:
Below is a summary table of the current analyst target prices discussed above:
|Name ||Symbol ||Recent Price ||Avg. Analyst 12-Mo. Target ||% Upside to Target|
|ProShares UltraPro Nasdaq Biotechnology ETF ||UBIO ||$31.45 ||$37.25 ||18.44%|
|Cytokinetics Inc ||CYTK ||$12.45 ||$22.67 ||82.06%|
|Aratana Therapeutics, Inc ||PETX ||$5.52 ||$10.00 ||81.16%|
|ChemoCentryx, Inc. ||CCXI ||$7.25 ||$13.00 ||79.31%|
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on CYTK — FREE
Get the latest Zacks research report on PETX — FREE
Get the latest Zacks research report on CCXI — FREE
Read the original article at ETF Channel: UBIO's Holdings Could Mean 18% Gain Potential
SDI Glossary: "Analyst" Definition
SDI Glossary: "Channel" Definition
SDI Glossary: "price" Definition
SDI Glossary: "ETFs" Definition
This Article's Word Cloud:
More articles: 1 2 3 4 5 6 7 next »